BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience

Business Of Biotech

We love to hear from our listeners. Send us a message.

From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way. Dr. Scherer discusses the balance between promising advances in T-cell therapy and the challenges associated with navigating a biotech from platform development to lead candidate status -- including staffing up for and funding the journey. Don't miss this episode, recorded in-person in San Francisco.
The 2025 BoB@JPM series is supported by Aslton & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience (00:00:00)

2. Biotech Transition From Medicine to Business (00:00:04)

3. Adapting Platform to Lead Compound (00:07:09)

4. Clinical Transition Challenges in Biotech (00:14:37)

5. Funding Clinical Development Challenges in Biotech (00:22:10)

6. JPMorgan Networking Opportunities in Biotech (00:32:57)

7. Collaboration in Biotech Development (00:42:14)